drugset / Trial / NCT04667975
The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy
Phase 1
Unknown
74 enrolled
Chong Kun Dang Pharmaceutical
Asan Medical Center · collabSamsung Medical Center · collabSeoul National University Hospital · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of study is to evaluate the safety, pharmacokinetics and anti-tumor effects of CKD-702 as a monotherapy and to determine the Recommended Phase 2 Dose(RP2D) in patients with advanced or metastatic non-small cell lung cancer who failed to standard therapy.
Timeline
- Start
- 2020-05-21
- Primary completion
- 2021-08-15
- Completion
- 2024-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CKD-702 | Unknown | 10 mg/kg | — |
| Subject | CKD-702 | Unknown | 15 mg/kg | — |
| Subject | CKD-702 | Unknown | 20 mg/kg | — |
| Subject | CKD-702 | Unknown | 25 mg/kg | — |